|
1
|
American Diabetes Association Professional
Practice Committee. Classification and diagnosis of diabetes: 2.
Diagnosis and Classification of Diabetes: Standards of Care in
Diabetes-2024. Diabetes Care. 47 (Suppl 1):S20–S42. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
International Diabetes Federation: IDF
Diabetes Atlas, 11th edition. Brussels, Belgium, IDF, 2025.
|
|
3
|
Khan MAB, et al: Global burden of diabetes
and its projections to 2050: A systematic review. Lancet Diabetes
Endocrinol, 2023.
|
|
4
|
Mooradian AD: Dyslipidemia in type 2
diabetes mellitus. Nat Clin Pract Endocrinol Metab. 5:150–159.
2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Caturano A, D'Angelo M, Mormone A, Russo
V, Mollica MP, Salvatore T, Galiero R, Rinaldi L, Vetrano E,
Marfella R, et al: Oxidative stress in type 2 diabetes: Impacts
from pathogenesis to lifestyle modifications. Curr Issues Mol Biol.
45:6651–6666. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Younossi ZM, Golabi P, Price JK, Owrangi
S, Gundu-Rao N, Satchi R and Paik JM: The global epidemiology of
nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
among patients with type 2 diabetes. Clin Gastroenterol Hepatol.
22:1999–2010.e8. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Younossi ZM, Kalligeros M and Henry L:
Epidemiology of metabolic dysfunction-associated steatotic liver
disease. Clin Mol Hepatol. 31 (Suppl):S32–S50. 2025.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Davies MJ, Aroda VR, Collins BS, Gabbay
RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C,
Mingrone G, et al: Management of hyperglycemia in type 2 diabetes,
2022. A consensus report by the American diabetes association (ADA)
and the european association for the study of diabetes (EASD).
Diabetes Care. 45:2753–2786. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Goedeke L and Shulman GI: Therapeutic
potential of mitochondrial uncouplers for the treatment of
metabolic associated fatty liver disease and NASH. Mol Metab.
46(101178)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Alexopoulos SJ, Chen SY, Brandon AE,
Salamoun JM, Byrne FL, Garcia CJ, Beretta M, Olzomer EM, Shah DP,
Philp AM, et al: Mitochondrial uncoupler BAM15 reverses
diet-induced obesity and insulin resistance in mice. Nat Commun.
11(2397)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kanemoto N, Okamoto T, Tanabe K, Shimada
T, Minoshima H, Hidoh Y, Aoyama M, Ban T, Kobayashi Y, Ando H, et
al: Antidiabetic and cardiovascular beneficial effects of a
liver-localized mitochondrial uncoupler. Nat Commun.
10(2172)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Figarola JL, Singhal J, Tompkins JD,
Rogers GW, Warden C, Horne D, Riggs AD, Awasthi S and Singhal SS:
SR4 Uncouples mitochondrial oxidative phosphorylation, modulates
AMP-dependent kinase (AMPK)-mammalian target of rapamycin (mTOR)
signaling, and inhibits proliferation of HepG2 hepatocarcinoma
cells. J Biol Chem. 290:30321–30341. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Singhal SS, Figarola J, Singhal J,
Nagaprashantha L, Berz D, Rahbar S and Awasthi S: Novel compound
1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progression.
Biochem Pharmacol. 86:1664–1672. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Figarola JL, Singhal J, Singhal S, Kusari
J and Riggs A: Bioenergetic modulation with the mitochondria
uncouplers SR4 and niclosamide prevents proliferation and growth of
treatment-naïve and vemurafenib-resistant melanomas. Oncotarget.
9:36945–36965. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rawling T, MacDermott-Opeskin H, Roseblade
A, Pazderka C, Clarke C, Bourget K, Wu X, Lewis W, Noble B, Gale
PA, et al: Aryl urea substituted fatty acids: A new class of
protonophoric mitochondrial uncoupler that utilises a synthetic
anion transporter. Chem Sci. 11:12677–12685. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
York E, McNaughton DA, Roseblade A,
Cranfield CG, Gale PA and Rawling T: Structure-activity
relationship and mechanistic studies of bisaryl urea anticancer
agents indicate mitochondrial uncoupling by a fatty Acid-Activated
Mechanism. ACS Chem Biol. 17:2065–2073. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Figarola JL, Singhal P, Rahbar S, Gugiu
BG, Awasthi S and Singhal SS: COH-SR4 reduces body weight, improves
glycemic control and prevents hepatic steatosis in high fat
diet-induced obese mice. PLoS One. 8(e83801)2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lau JK, Zhang X and Yu J: Animal models of
non-alcoholic fatty liver disease: Current perspectives and recent
advances. J Pathol. 241:36–44. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Benedé-Ubieto R, Estévez-Vázquez O,
Ramadori P, Cubero FJ and Nevzorova YA: Guidelines and
considerations for metabolic tolerance tests in mice. Diabetes
Metab Syndr Obes. 13:439–450. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Noeman SA, Hamooda HE and Baalash AA:
Biochemical study of oxidative stress markers in the liver, kidney
and heart of high fat diet induced obesity in rats. Diabetol Metab
Syndr. 3(17)2011.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fraga CG, Leibovitz BE and Tappel AL:
Lipid peroxidation measured as thiobarbituric acid-reactive
substances in tissue slices: Characterization and comparison with
homogenates and microsomes. Free Radic Biol Med. 4:155–1561.
1988.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Iuso A, Repp B, Biagosch C, Terrile C and
Prokisch H: Assessing mitochondrial bioenergetics in isolated
mitochondria from various mouse tissues using Seahorse XF96
analyzer. Methods Mol Biol. 1567:217–230. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A Bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140.
2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15(550)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Goedhart J and Luijsterburg MS: VolcaNoseR
is a web app for creating, exploring, labeling and sharing volcano
plots. Sci Rep. 10(20560)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Huang DW, Sherman BT, Lempicki RA and
Lemoine S: DAVID: A web server for functional enrichment analysis
and functional annotation of gene lists (2021 update). Nucleic
Acids Res. 50:W216–W221. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Szklarczyk D, Nastou K, Koutrouli M,
Kirsch R, Mehryary F, Hachilif R, Hu D, Peluso ME, Huang Q, Fang T,
et al: The STRING database in 2025: Protein networks with
directionality of regulation. Nucleic Acids Res. 53:D730–D737.
2025.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4(2)2003.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 (Suppl 4)(S11)2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Burke SJ, Batdorf HM, Burk DH, Noland RC,
Eder AE, Boulos MS, Karlstad MD and Collier JJ: Db/db mice exhibit
features of human type 2 diabetes that are not present in
weight-matched C57BL/6J mice fed a Western diet. J Diabetes Res.
2017(8503754)2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sahai A, Malladi P, Pan X, Paul R,
Melin-Aldana H, Green RM and Whitington PF: Obese and diabetic
db/db mice develop marked liver fibrosis in a model of nonalcoholic
steatohepatitis: Role of short-form leptin receptors and
osteopontin. Am J Physiol Gastrointest Liver Physiol.
287:G1035–G1043. 2004.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhao H, Matsuzaka T, Nakano Y, Motomura K,
Tang N, Yokoo T, Okajima Y, Han SI, Takeuchi Y, Aita Y, et al:
Elovl6 deficiency improves glycemic control in diabetic db/db mice
by expanding β-Cell mass and increasing insulin secretory capacity.
Diabetes. 66:1833–1846. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Matsuzaka T, Atsumi A, Matsumori R, Nie T,
Shinozaki H, Suzuki-Kemuriyama N, Kuba M, Nakagawa Y, Ishii K,
Shimada M, et al: Elovl6 promotes nonalcoholic steatohepatitis.
Hepatology. 56:2199–2208. 2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Xiao Y, Batmanov K, Hu W, Zhu K, Tom AY,
Guan D, Jiang C, Cheng L, McCright SJ, Yang EC, et al: Hepatocytes
demarcated by EphB2 contribute to the progression of nonalcoholic
steatohepatitis. Sci Transl Med. 15(eadc9653)2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Mimche PN, Lee CM, Mimche SM, Thapa M,
Grakoui A, Henkemeyer M and Lamb TJ: EphB2 receptor tyrosine kinase
promotes hepatic fibrogenesis in mice via activation of hepatic
stellate cells. Sci Rep. 8(2532)2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhou L, Xu L, Ye J, Li D, Wang W, Li X, Wu
L, Wang H, Guan F and Li P: Cidea promotes hepatic steatosis by
sensing dietary fatty acids. Hepatology. 56:95–107. 2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sans A, Bonnafous S, Rousseau D, Patouraux
S, Canivet CM, Leclere PS, Tran-Van-Nhieu J, Luci C, Bailly-Maitre
B, Xu X, et al: The differential expression of Cide family members
is associated with NAFLD progression from steatosis to
steatohepatitis. Sci Rep. 9(7501)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Simmen FA, Pabona JMP, Al-Dwairi A,
Alhallak I, Montales MTE and Simmen RCM: Malic enzyme 1 (ME1)
promotes adiposity and hepatic steatosis and induces circulating
insulin and leptin in obese female mice. Int J Mol Sci.
24(6613)2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Al-Dwairi A, Pabona JM, Simmen RC and
Simmen FA: Cytosolic malic enzyme 1 (ME1) mediates high fat
diet-induced adiposity, endocrine profile, and gastrointestinal
tract proliferation-associated biomarkers in male mice. PLoS One.
7(e46716)2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Batista TM, Dagdeviren S, Carroll SH, Cai
W, Melnik VY, Noh HL, Saengnipanthkul S, Kim JK, Kahn CR and Lee
RT: Arrestin domain-containing 3 (Arrdc3) modulates insulin action
and glucose metabolism in liver. Proc Natl Acad Sci USA.
117:6733–6740. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Patwari P, Emilsson V, Schadt EE, Chutkow
WA, Lee S, Marsili A, Zhang Y, Dobrin R, Cohen DE, Larsen PR, et
al: The arrestin domain-containing 3 protein regulates body mass
and energy expenditure. Cell Metab. 14:671–683. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Dorn C, Riener MO, Kirovski G, Saugspier
M, Steib K, Weiss TS, Gäbele E, Kristiansen G, Hartmann A and
Hellerbrand C: Expression of fatty acid synthase in nonalcoholic
fatty liver disease. Int J Clin Exp Pathol. 3:505–514.
2010.PubMed/NCBI
|
|
45
|
O'Farrell M, Duke G, Crowley R, Buckley D,
Martins EB, Bhattacharya D, Friedman SL and Kemble G: FASN
inhibition targets multiple drivers of NASH by reducing steatosis,
inflammation and fibrosis in preclinical models. Sci Rep.
12(15661)2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mateo-Marín MA and Alves-Bezerra M:
Targeting acetyl-CoA carboxylases for the treatment of MASLD. J
Lipid Res. 65(100676)2024.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tamura YO, Sugama J, Iwasaki S, Sasaki M,
Yasuno H, Aoyama K, Watanabe M, Erion DM and Yashiro H: Selective
Acetyl-CoA carboxylase 1 inhibitor improves hepatic steatosis and
hepatic fibrosis in a preclinical nonalcoholic steatohepatitis
model. J Pharmacol Exp Ther. 379:280–289. 2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Jamwal R, de la Monte SM, Ogasawara K,
Adusumalli S, Barlock BB and Akhlaghi F: Nonalcoholic fatty liver
disease and diabetes are associated with decreased CYP3A4 protein
expression and activity in human liver. Mol Pharm. 15:2621–2632.
2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Woolsey SJ, Mansell SE, Kim RB, Tirona RG
and Beaton MD: CYP3A activity and expression in nonalcoholic fatty
liver disease. Drug Metab Dispos. 43:1484–1490. 2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ping DB, Sun X, Peng Y and Liu CH:
Cyp4a12-mediated retinol metabolism in stellate cells is the
antihepatic fibrosis mechanism of the Chinese medicine Fuzheng
Huayu recipe. Chin Med. 18(51)2023.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Theken KN, Deng Y, Kannon MA, Miller TM,
Poloyac SM and Lee CR: Activation of the acute inflammatory
response alters cytochrome P450 expression and eicosanoid
metabolism. Drug Metab Dispos. 39:22–29. 2011.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Li X, Zhong S, Sun Y, Huang X, Li Y, Wang
L, Wu Y, Yang M, Yuan HX, Liu J and Zang S: Integration analysis
identifies the role of metallothionein in the progression from
hepatic steatosis to steatohepatitis. Front Endocrinol (Lausanne).
13(951093)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Guan C, Zou X, Shi W, Gao J, Yang C, Ge Y,
Xu Z, Bi S and Zhong X: Metallothionein 1B attenuates inflammation
and hepatic steatosis in MASH by inhibiting the AKT/PI3K pathway. J
Lipid Res. 66(100701)2025.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Laila UE, Zhao ZL, Xu DY, Liu H and Xu ZX:
Pharmacological advances and therapeutic applications of
niclosamide in cancer and other diseases. Eur J Med Chem.
290(117527)2025.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Park KS, Jo I, Pak K, Bae SW, Rhim H, Suh
SH, Park J, Zhu H, So I and Kim KW: FCCP depolarizes plasma
membrane potential by activating proton and Na+ currents in bovine
aortic endothelial cells. Pflugers Arch. 443:344–352.
2002.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Vilar-Gomez E, Martinez-Perez Y,
Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B,
Gonzalez-Fabian L, Friedman SL, Diago M and Romero-Gomez M: Weight
loss through lifestyle modification significantly reduces features
of nonalcoholic steatohepatitis. Gastroenterology. 2:367–378.
2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Wilding JP: The importance of weight
management in type 2 diabetes mellitus. Int J Clin Pract.
68:682–691. 2014.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Neeland IJ, Linge J and Birkenfeld AL:
Changes in lean body mass with glucagon-like peptide-1-based
therapies and mitigation strategies. Diabetes Obes Metab. 26 (Suppl
4):S16–S27. 2024.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Cava E, Yeat NC and Mittendorfer B:
Preserving healthy muscle during weight loss. Adv Nutr. 8:511–519.
2017.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Hardie DG, Ross FA and Hawley SA: AMPK: A
nutrient and energy sensor that maintains energy homeostasis. Nat
Rev Mol Cell Biol. 13:251–262. 2012.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Tai T, Shao YY, Zheng YQ, Jiang LP, Han
HR, Yin N, Li HD, Ji JZ, Mi QY, Yang L, et al: Clopidogrel
ameliorates High-fat diet-induced hepatic steatosis in mice through
activation of the AMPK signaling pathway and beyond. Front
Pharmacol. 15(1496639)2024.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Wang Y, Liu S, Ni M, Chen Y, Chen R, Wang
J, Jiang W, Zhou T, Fan S, Chang J, et al: Terf2ip deficiency
accelerates non-alcoholic steatohepatitis through regulating
lipophagy and fatty acid oxidation via Sirt1/AMPK pathway. Free
Radic Biol Med. 220:78–91. 2024.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Matsusue K, Haluzik M, Lambert G, Yim SH,
Gavrilova O, Ward JM, Brewer B Jr, Reitman ML and Gonzalez FJ:
Liver-specific disruption of PPARgamma in leptin-deficient mice
improves fatty liver but aggravates diabetic phenotypes. J Clin
Invest. 111:737–747. 2003.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Baumann A, Burger K, Brandt A, Staltner R,
Jung F, Rajcic D, Lorenzo Pisarello MJ and Bergheim I: GW9662, a
peroxisome proliferator-activated receptor gamma antagonist,
attenuates the development of non-alcoholic fatty liver disease.
Metabolism. 133(155233)2022.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Sozio MS, Lu C, Zeng Y, Liangpunsakul S
and Crabb DW: Activated AMPK inhibits PPARα and PPARγ
transcriptional activity in hepatoma cells. Am J Physiol
Gastrointest Liver Physiol. 301:G739–G747. 2011.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Blanchard PG, Festuccia WT, Houde VP,
St-Pierre P, Brûlé S, Turcotte V, Côté M, Bellmann K, Marette A and
Deshaies Y: Major involvement of mTOR in the PPARγ-induced
stimulation of adipose tissue lipid uptake and fat accretion. J
Lipid Res. 53:1117–1125. 2012.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Hunter CA, Kartal F, Koc ZC, Murphy T, Kim
JH, Denvir J and Koc EC: Mitochondrial oxidative phosphorylation is
impaired in TALLYHO mice, a new obesity and type 2 diabetes animal
model. Int J Biochem Cell Biol. 116(105616)2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Xiong G, Zhang K, Ma Y, Song Y, Zhang W,
Qi T, Qiu H, Shi J, Kan C, Zhang J and Sun X: BAM15 as a
mitochondrial uncoupler: A promising therapeutic agent for diverse
diseases. Front Endocrinol (Lausanne). 14(1252141)2023.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Yoo HC, Yu YC, Sung Y and Han JM:
Glutamine reliance in cell metabolism. Exp Mol Med. 52:1496–1516.
2020.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Amores-Sánchez MI and Medina MA:
Glutamine, as a precursor of glutathione, and oxidative stress. Mol
Genet Metab. 67:100–105. 1999.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Torres N, Tobón-Cornejo S,
Velazquez-Villegas LA, Noriega LG, Alemán-Escondrillas G and Tovar
AR: Amino acid catabolism: An overlooked area of metabolism.
Nutrients. 15(3378)2023.PubMed/NCBI View Article : Google Scholar
|
|
72
|
TeSlaa T, Ralser M, Fan J and Rabinowitz
JD: The pentose phosphate pathway in health and disease. Nat Metab.
5:1275–1289. 2023.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Dungubat E, Kusano H, Mori I, Tawara H,
Sutoh M, Ohkura N, Takanashi M, Kuroda M, Harada N, Udo E, et al:
Age-dependent sex difference of non-alcoholic fatty liver disease
in TSOD and db/db mice. PLoS One. 17(e0278580)2022.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Chen SY, Beretta M, Olzomer EM,
Alexopoulos SJ, Shah DP, Byrne FL, Salamoun JM, Garcia CJ, Smith
GC, Larance M, et al: Head-to-head comparison of BAM15,
semaglutide, rosiglitazone, NEN, and calorie restriction on
metabolic physiology in female db/db mice. Biochim Biophys Acta Mol
Basis Dis. 1870(166908)2024.PubMed/NCBI View Article : Google Scholar
|
